BillionToOne SVP Sells 1,416 Shares
Key Points
The transaction involved 1,416 shares at a weighted average price of $97.54 per share, totaling $138,116 on Sept. 9, 2026.
The sale involved shares equal to 5% of the direct equity position held before the transaction.
The disposition was executed directly under a Rule 10b5-1 trading plan.
The transaction reflects routine liquidity management following the plan's adoption in June 2026.
- 10 stocks we like better than BillionToOne ›
John Roderick Ten Bosch, SVP of Laboratory Operations at BillionToOne, Inc. (NASDAQ:BLLN), sold 1,416 shares of Class A Common Stock on Sept. 9, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | ~$138,117 |
| Shares sold (direct) | 1,416 |
| Post-transaction shares (directly held) | 25,051 |
| Post-transaction value | $2.4 million |
Transaction value based on SEC Form 4 weighted average sale price ($97.54); post-transaction value based on September 09, 2026, market close ($99.16).
Key questions
- How does this sale align with the insider's total direct position?
Following the sale of 1,416 shares, John Roderick Ten Bosch maintains a direct position of 25,051 shares, which represented a market value of $2.4 million as of the Sept. 9, 2026, market close. - What regulatory framework governed this transaction?
The trade was conducted under a Rule 10b5-1 plan adopted on June 2, 2026, which establishes a systematic trading cadence to manage equity holdings for company executives. - What is the broader context of insider equity at BillionToOne?
Total insider ownership across the company is 0.0545%, according to the latest available data, as the firm continues to develop specialized diagnostics and its molecular counting platform. - Does this transaction indicate a shift in management sentiment?
The transaction was executed via a pre-established trading plan and represents a single-digit percentage of the insider's total holdings, suggesting routine portfolio management.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-11) | $98.77 |
| Market Capitalization | $4.6 billion |
| Revenue (TTM) | $397.4 million |
| Net Income (TTM) | $31.9 million |
Company Snapshot
- BillionToOne develops and commercializes advanced molecular diagnostic solutions, including the UNITY Complete non-invasive prenatal screening platform, which leverages proprietary DNA molecule-counting technology to enhance the precision of disease detection.
- The company generates revenue through the sale of diagnostic testing services and products that utilize its cutting-edge molecular counting platform to quantify biological data with exceptional accuracy.
- BillionToOne serves healthcare providers, clinical laboratories, and patients seeking advanced prenatal and molecular diagnostic testing, targeting the growing market for non-invasive and precision diagnostic solutions.
BillionToOne is a specialized diagnostics company with a $4.6 billion market capitalization and 713 employees, based in Menlo Park, California. The company has achieved TTM revenue of $397 million and net income of $32 million, demonstrating profitability as it scales its molecular diagnostic platform.
BillionToOne's competitive advantage lies in its proprietary technology for the precise quantification of DNA molecules, enabling superior accuracy in disease detection and positioning the company as an innovator in the medical diagnostics and research sector.
What this transaction means for investors
This sale shouldn't concern investors. It was completed under a Rule 10b5-1 plan, indicating a routine liquidity event for personal financial management reasons. Moreover, the insider retains over 25,000 shares of the company's stock.
BillionToOne continues to grow rapidly, with revenue surging 64% year over year in the second quarter. It's also turning a small operating profit, although margins have been lower in the first half of the year due to higher research and development spending.
The stock trades at a high multiple of sales and earnings, with analysts expecting revenue growth to be around 37% on an annualized basis over the next two years.
Should you buy stock in BillionToOne right now?
Before you buy stock in BillionToOne, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BillionToOne wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $387,158!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,365,749!*
Now, it’s worth noting Stock Advisor’s total average return is 932% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 21, 2026.
John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BillionToOne. The Motley Fool has a disclosure policy.
Recommended Articles
